MedTrace Logo

A Screening Study Targeting Tumor-specific Antigens

NCT05158621 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2022-10-18

No results posted yet for this study

Summary

The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by Gritstone bio. This may include the manufacturing of an individualized vaccine, which involves neoantigen prediction and generating a vaccine targeting neoantigens.

Conditions

Interventions

PROCEDURE

blood collection for research (next generation sequencing [NGS])

participants will have whole blood collected for NGS

PROCEDURE

blood collection for research (HLA typing)

participants will have whole blood collected for HLA typing

PROCEDURE

blood collection for research (circulating tumor DNA [ctDNA])

participants will have whole blood collected for ctDNA detection

Sponsors & Collaborators

  • Gritstone bio, Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2022-08-15
Completion
2022-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158621 on ClinicalTrials.gov